Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 3771249 as Monotherapy or in Combination With Cetuximab in Advanced/Metastatic Colorectal Cancer With KRAS G12D Mutation
NCT07535112Phase 1Recruiting
- Sponsor
- Bayer
- Start
- Apr 2026
- Primary completion
- Jul 2029
- Modality
- Covalent Small Molecules
- Countries
- 10
01
Overview
Phase 1, randomised, open-label trial of KQB548 in colorectal adenocarcinoma (2 arms), sponsored by Bayer. Primary endpoints: Change from baseline in laboratory test results at 2 years, Change from baseline in vital signs: Blood pressure at 2 years and 8 more. Started Apr 2026; status: recruiting.
02
Drugs
KQB548
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on NCT07535112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07535112.